Clinical trial · no report yet · Phase 2
DEBBRAH
DS-8201a for trEatment of aBc, BRain Mets, And Her2[+] Disease
- NCT04420598 ↗
- Completed
- MedSIR
- 12 commentary sources found
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| Podcasts | 5 | |
| YouTube | 4 | |
| X threads | 3 |
The trial
ClinicalTrials.gov- Official title
- Multicenter, Open-Label, Single-Arm, Multicohort Phase II Clinical Trial of Trastuzumab Deruxtecan(DS-8201a) in Human Epidermal Growth Factor Receptor 2 HER2+ Advanced Breast Cancer With Brain Metastases and/or Leptomeningeal Carcinomatosis
- Phase
- Phase 2
- Status
- Completed
- Conditions
- Advanced Breast Cancer; HER2-positive Breast Cancer; Brain Metastases; Leptomeningeal Metastasis
- Interventions
- Trastuzumab deruxtecan
- Arms
- Trastuzumab deruxtecan (DS-8201a) · Experimental
- Enrollment
- 41
- Primary outcomes
- 16 Weeks PFS Per Response Assessment in Neuro-Oncology Brain Metastases (RANO-BM) (Cohort 1)
- Objective Response Rate According RANO-BM (Cohorts 2, 3 and 4)
- Overall Survival in Cohort 5
- Sponsor
- MedSIR with Daiichi Sankyo
- Start
- May 25, 2020
- Primary completion
- Sep 30, 2021
- Results posted
- Yes
- Registry record
- NCT04420598 · updated Jun 24, 2025
Publications
linked from the registry- Vaz Batista M, Perez-Garcia JM, Garrigos L, Garcia-Saenz JA, Cortez P, Racca F, Blanch S, Ruiz-Borrego M, Fernandez-Ortega A, Fernandez-Abad M, Iranzo V, Gion M, Martrat G, Alcala-Lopez D, Perez-Escuredo J, Sampayo-Cordero M, Llombart-Cussac A, Braga S, Cortes J. The DEBBRAH trial: Trastuzumab deruxtecan in HER2-positive and HER2-low breast cancer patients with leptomeningeal carcinomatosis. Med. 2025 Jan 10;6(1):100502. doi: 10.1016/j.medj.2024.08.001. Epub 2024 Sep 11. PubMed 39265579
- Vaz Batista M, Perez-Garcia JM, Cortez P, Garrigos L, Fernandez-Abad M, Gion M, Martinez-Bueno A, Saavedra C, Teruel I, Fernandez-Ortega A, Servitja S, Ruiz-Borrego M, de la Haba-Rodriguez J, Martrat G, Perez-Escuredo J, Alcala-Lopez D, Sampayo-Cordero M, Braga S, Cortes J, Llombart-Cussac A. Trastuzumab deruxtecan in patients with previously treated HER2-low advanced breast cancer and active brain metastases: the DEBBRAH trial. ESMO Open. 2024 Sep;9(9):103699. doi: 10.1016/j.esmoop.2024.103699. Epub 2024 Sep 9. PubMed 39255534